Patents by Inventor Jochen Buck
Jochen Buck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220402017Abstract: A textile machine tool part (11) that is used in textile processing in a textile machine and a method for producing same are disclosed. The textile machine tool part (11) has a tool core (16) made of a core material and is coated, at least in part, with a wear-resistant coating. The wear-resistant coating (17) is applied to a core surface (18) that has a first microstructure (19). The first microstructure (19) is preferably created using electrochemical etching in the core surface (18). The wear-resistant coating (17) applied thereto is preferably applied directly to at least a section of the core surface (18) having the first microstructure (19) using electrochemical deposition and has a layer thickness of a maximum of 20 ?m.Type: ApplicationFiled: August 24, 2022Publication date: December 22, 2022Inventors: Jochen Buck, Thomas Goller, Sven Beis
-
Publication number: 20210245231Abstract: The invention relates to a textile machine tool part (11) that is used in textile processing in a textile machine and to a method for producing same. The textile machine tool part (11) has a tool core (16) made of a core material and is coated, at least in part, with a wear-resistant coating. The wear-resistant coating (17) is applied to a core surface (18) that has a first microstructure (19). The first microstructure (19) is preferably created using electrochemical etching in the core surface (18). The wear-resistant coating (17) applied thereto is preferably applied directly to at least a section of the core surface (18) having the first microstructure (19) using electrochemical deposition and has a layer thickness of a maximum of 20 ?m.Type: ApplicationFiled: July 19, 2018Publication date: August 12, 2021Inventors: Jochen Buck, Thomas Goller, Sven Beis
-
Patent number: 10981899Abstract: Provided are 6-amino substituted 2,6-diamino-4-chloropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.Type: GrantFiled: April 28, 2017Date of Patent: April 20, 2021Assignees: Cornell University, Tri-Institutional Therapeutics Discovery InstituteInventors: Jochen Buck, Lonny Levin, Lavoisier Ramos-Espiritu, Clemens Steegborn, Ayumu Sato, Rei Okamoto, Mayako Michino
-
Publication number: 20200157084Abstract: Provided are 6-amino substituted 2,6-diamino-4-choropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.Type: ApplicationFiled: April 28, 2017Publication date: May 21, 2020Inventors: Jochen BUCK, Lonny LEVIN, Lavoisier RAMOS-ESPIRITU, Clemens STEEGBORN, Ayumu SATO, Rei OKAMOTO, Mayako MICHINO
-
Patent number: 9649295Abstract: The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of: learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, and peripheral neuropathy. The method involves modulating soluble adenylyl cyclase in the subject. Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.Type: GrantFiled: January 20, 2005Date of Patent: May 16, 2017Assignees: Cornell Research Foundation, Inc., Kent UniversityInventors: Jochen Buck, Lonny R. Levin, Fritz A. Muhlschlegel
-
Patent number: 9388250Abstract: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.Type: GrantFiled: February 23, 2010Date of Patent: July 12, 2016Assignee: CORNELL UNIVERSITYInventors: Jochen Buck, Lonny Levin, Jonathan Zippin
-
Patent number: 9095578Abstract: The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.Type: GrantFiled: January 11, 2008Date of Patent: August 4, 2015Assignee: CORNELL RESEARCH FOUNDATION, INC.Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
-
Patent number: 9017681Abstract: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.Type: GrantFiled: January 11, 2008Date of Patent: April 28, 2015Assignee: Cornell Research Foundation, Inc.Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
-
Patent number: 8859213Abstract: The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.Type: GrantFiled: April 6, 2011Date of Patent: October 14, 2014Assignee: Cornell UniversityInventors: Cynthia Magro, Jonathan Zippin, Lonny R. Levin, Jochen Buck
-
Publication number: 20130065246Abstract: The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.Type: ApplicationFiled: April 6, 2011Publication date: March 14, 2013Applicant: CORNELL UNIVERSITYInventors: Cynthia Magro, Jonathan Zippin, Lonny R. Levin, Jochen Buck
-
Publication number: 20110305640Abstract: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.Type: ApplicationFiled: February 23, 2010Publication date: December 15, 2011Applicant: CORNELL UNIVERSITYInventors: Jochen Buck, Lonny Levin, Jonathan Zippin
-
Publication number: 20100168203Abstract: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.Type: ApplicationFiled: January 11, 2008Publication date: July 1, 2010Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
-
Publication number: 20100063099Abstract: The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.Type: ApplicationFiled: January 11, 2008Publication date: March 11, 2010Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi, Leo Brizuela, Michael Pinnisi
-
Publication number: 20080152652Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.Type: ApplicationFiled: August 3, 2007Publication date: June 26, 2008Inventors: Peter Besmer, Jochen Buck, Malcolm A.S. Moore, Karl Nocka
-
Publication number: 20070244174Abstract: The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of: learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, and peripheral neuropathy. The method involves modulating soluble adenylyl cyclase in the subject. Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.Type: ApplicationFiled: January 20, 2005Publication date: October 18, 2007Inventors: Jochen Buck, Lonny Levin, Fritz Muhlschlegel
-
Publication number: 20050276784Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.Type: ApplicationFiled: November 12, 2004Publication date: December 15, 2005Inventors: Peter Besmer, Jochen Buck, Malcolm Moore, Karl Nocka
-
Publication number: 20030125519Abstract: This invention provides an isolated nucleic acid molecule which encodes an amino acid sequence corresponding to a c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof. A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.Type: ApplicationFiled: October 5, 1990Publication date: July 3, 2003Inventors: PETER BESMER, KARL NOCKA, JOCHEN BUCK
-
Publication number: 20030103937Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.Type: ApplicationFiled: April 24, 2002Publication date: June 5, 2003Applicant: Sloan-Kettering Institute For Cancer ResearchInventors: Peter Besmer, Jochen Buck, Malcolm A.S. Moore, Karl Nocka
-
Patent number: 6544768Abstract: The invention provides isolated animal soluble adenylyl cyclase and methods of modulating its expression and activity. Also provided are methods of utilizing soluble adenylyl cyclase for diagnosing pathological conditions and monitoring blood gases.Type: GrantFiled: May 11, 2000Date of Patent: April 8, 2003Assignee: Cornell Research Foundation, Inc.Inventors: Jochen Buck, Lonny R. Levin
-
Patent number: 6403559Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.Type: GrantFiled: August 10, 1999Date of Patent: June 11, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Peter Besmer, Jochen Buck, Malcolm A. S. Moore, Karl Nocka